Soleus Capital Master Fund, L.P. has disclosed a substantial investment in Palisade Bio, Inc., holding approximately 8.6% of the company's common stock. This filing, made on November 9, 2026, is a significant move that underscores Soleus Capital's confidence in the potential of Palisade Bio and its position within the biological products industry.

Palisade Bio, Inc. operates in the biological products sector, focusing on innovative therapies and solutions. The company is incorporated in Delaware and is headquartered in Denver, Colorado. It has undergone name changes in the past, previously known as Seneca Biopharma, Inc. and Neuralstem, Inc. The filing indicates that as of August 6, 2026, Palisade Bio had 174,270,558 shares of common stock outstanding, providing context for Soleus Capital's reported stake.

The recent filing reveals that Soleus Capital Master Fund, L.P. holds 14,996,154 shares of Palisade Bio, which are classified as common stock with a par value of $0.01 per share. The filing also notes that Soleus Capital, LLC is the sole general partner of the Master Fund, with Guy Levy serving as the managing member of both Soleus Capital, LLC and Soleus Capital Group, LLC. Notably, the filing states that these shares are held directly by the Master Fund, and the ownership is shared among several entities and individuals associated with Soleus Capital.

This significant stake may influence Palisade Bio's strategic decisions moving forward, as Soleus Capital's involvement could lead to increased scrutiny and support for the company's initiatives. The filing indicates that the shares were not acquired with the intent to influence control of Palisade Bio, which may suggest a focus on investment rather than active management.

As the biological products industry continues to evolve, Soleus Capital's investment reflects broader trends in the market, highlighting the potential for growth and innovation. The filing does not specify what actions may follow this disclosure, leaving the future trajectory of both Soleus Capital and Palisade Bio open to speculation.

Details were not available in the SEC filing regarding any upcoming votes or additional filings related to this investment.